Clinical Benefit and Risk Evaluation of Neoadjuvant Treatment for HER2+ Early Breast Cancer (EBC)

Consensus Statement	Quality of Evidence	Strength of Rec.	Key Ref
1. Neoadjuvant therapy is the preferred treatment approach for patients with high-risk HER2-positive breast cancer, defined as tumor size ≥T2 or clinically node-positive disease.	I	A	1,2
2. The neoadjuvant treatment platform may be used for patients with intermediate risk defined as T1cN0 to individualize subsequent therapeutic strategies according to the patient’s clinical and/or pathologic response.	II	A	3,4

References